AI4LUNGS
AI4LUNGS is an €6.9 million EU Horizon Europe research consortium developing an AI-powered clinical decision support platform with digital twin technology and multi-modal data analysis for respiratory disease diagnosis and stratification, serving clinicians across 18 partner institutions in 10 countries.
- Company typePrivate
- Founded2024
- HeadquartersPorto Carreiro, Portugal
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What AI4LUNGS does
AI4LUNGS is a €6.9 million, 42-month EU-funded research consortium that commenced on 1 January 2024 under the Horizon Europe Programme (Grant Agreement No. 101080756). Coordinated by INESC TEC (Portugal) and disseminated by Future Needs Management Consulting Ltd (Cyprus), it brings together 18 partners across 10 countries — including clinical centers, academic researchers, technical engineering firms, legal specialists, and consultancies — to develop and validate AI-based tools for diagnosing and treating infectious and non-infectious respiratory diseases. The consortium addresses the HORIZON-HLTH-2022-TOOL-12 call and is positioned as a Research Innovation Action rather than a commercial entity.
The consortium's core offering is the AI4LUNGS Platform, which integrates machine and deep learning algorithms, a Digital Twin system for patient simulation, multi-modal data analysis (medical imaging, electronic health records, clinical registries, digital auscultation, liquid biopsy, and molecular profiling), natural language processing, and semantic data processing. These capabilities are packaged into an AI-powered clinical decision support system designed to surface imaging characteristics invisible to the human eye and produce personalized treatment recommendations along the patient stratification pathway. The platform is being validated through two clinical pilot programs and has accumulated over 2,500 real-world patient records from clinical centers in Portugal, Spain, the Netherlands, and Israel, plus the Cancer Registry of Norway.
AI4LUNGS is not a commercial company and does not sell products or services. Its €6.9 million in funding is a non-dilutive EU grant with no equity instruments, and the consortium operates under Cyprus and EU law. End users are clinicians at participating medical centers who deploy the platform within their daily routines; commercial revenue is not generated, and any future commercialization is contingent on regulatory outcomes under the EU AI Act and related frameworks, with dedicated legal partner Timelex guiding compliance from project inception. The primary "customer" relationships are therefore research and data-sharing partnerships with hospitals and cancer registries rather than fee-paying buyers.
AI4LUNGS firmographics
Firmographics- Name
- AI4LUNGS
- Legal name
- FUTURE NEEDS MANAGEMENT CONSULTING LTD
- Website
- https://ai4lungs.eu
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- AI4LUNGS is an €6.9 million EU Horizon Europe research consortium developing an AI-powered clinical decision support platform with digital twin technology and multi-modal data analysis for respiratory disease diagnosis and stratification, serving clinicians across 18 partner institutions in 10 countries.
- Ownership category
- akta.pro rank
AI4LUNGS industry classification
Industry- Product category
- Clinical Decision Support Systems
- NAICS
- Custom Computer Programming Services (541511), Software Publishers (513210), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Computer Programming Services (7371), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI) (HDAEANAI), AI/ML Engineering & Model Development Services (BPAEAHAF)
Keywords
Where AI4LUNGS is headquartered
LocationHeadquarters
- HQ city
- Porto Carreiro
- HQ country
- Portugal
- HQ region
- Europe
Offices3 records
Markets served
AI4LUNGS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- EU Research Grant Funding: Funded by the European Union under the Horizon Europe Programme (Grant Agreement No. 101080756) with €6.9 million allocated for the 42-month research project. This is a non-revenue generating research initiative focused on developing and validating AI-based tools rather than commercializing products.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels9 records
AI4LUNGS product offering
Product offeringCore offering
AI4LUNGS develops an AI-based software platform for the diagnosis, prognosis, and treatment of respiratory diseases including lung cancer, ILD, IPF, COPD, and COVID-19. The platform combines multi-modal data integration, digital twin technology, and clinical decision support tools to provide guideline-based and AI-generated recommendations for clinicians managing respiratory patients.
Product overview
AI4LUNGS is a 42-month EU-funded research project (Grant Agreement No. 101080756) developing an AI-driven healthcare platform for respiratory disease diagnosis and treatment. The core offering is the AI4LUNGS Platform, which integrates machine and deep learning algorithms with a Digital Twin System and AI-Powered Clinical Decision Support capabilities. The platform collects multi-modal patient data (imaging, clinical records, digital auscultation, molecular profiles) to create personalized diagnostic and treatment recommendations. The system is designed to support clinicians in decision-making along the patient journey from initial suspicion to diagnosis and treatment planning, with a focus on infectious and non-infectious respiratory diseases. The platform is deployed on a single integrated system for clinicians to use in daily routines, with secure data handling through Yonalink and validation from clinical pilots across 10 countries.
Differentiator
Problem solved
Functional benefit
Products and services
- AI4LUNGS Platform Integrated AI-based clinical decision support platform combining multi-modal data, digital twin technology, and machine learning to assist healthcare professionals in diagnosing, prognosticating, and treating respiratory diseases including lung cancer, ILD, IPF, COPD, and COVID-19.
- Digital Twin System Digital twin technology component that creates virtual patient models using multi-modal clinical, imaging, and patient-reported data to support personalized diagnosis and treatment planning for respiratory diseases.
- AI-Powered Clinical Decision Support System Decision support tool that delivers guideline-based recommendations augmented with AI-generated suggestions to clinicians managing respiratory disease patients, integrating data from multiple sources including medical imaging, electronic health records, and patient-reported outcomes.
Companies that use AI4LUNGS
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
AI4LUNGS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
AI4LUNGS partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core.
- INESC TECcoreProject Coordinator of AI4LUNGS. Non-profit research institute in Portugal providing scientific research, technological development, and coordination of AI analytic models for personalized lung healthcare treatment. Representatives include Hélder P. Oliveira, Duarte Dias, and Ana Maria Mendonça.
- Future Needs Management Consulting LtdcoreDissemination, Communication, and Sustainable Exploitation Leader responsible for ensuring the project's research reaches clinicians, researchers, policymakers, and the public. Based in Nicosia, Cyprus. Thanos Arvanitidis serves as Project Manager.
- TimelexcoreLegal partner specializing in EU AI Act and GDPR compliance, co-developing digital ethics principles, training partners on regulations, and ensuring responsible data processing. Led by Magdalena Kogut-Czarkowska.
- DeloittecoreDigital ethics expert providing insights on ethical AI implementation, human-in-the-loop approaches, and responsible integration of AI tools into clinical workflows. Led by Marcel Rebbert.
- YonalinkcoreData collection and management platform ensuring secure and efficient transfer of clinical data from participating medical centers to KPMG for analysis and AI model training. Led by Itai Rechnitz, COO & Co-founder.
- KPMG (Somekh Chaikin Partnership)coreTechnical partner responsible for AI model training and analysis using pseudonymised data transferred via Yonalink platform.
- Fraunhofer ITWMcoreTechnical partner building robust, privacy-preserving infrastructures for AI tools, contributing to secure cloud environments and controlled data access systems.
- EXUS SoftwarecoreTechnical partner contributing to the AI4LUNGS platform development and data transfer infrastructure.
- RPTU (Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau)coreTechnical partner and university contributing to AI platform development and hosting project meetings.
- CERGAS SDA Bocconi School of ManagementcoreDeveloping a new framework for health technology assessment for artificial intelligence; understanding benefits for patient diagnoses and pathway improvement in chronic lung diseases. Led by Michela Meregaglia. Hosted the 2026 Open Workshop.
- Stichting Amsterdam UMC (AMC)coreData Provider and Data Controller. Obtains ethics approvals, collects data ethically, and ensures data is anonymised or pseudonymised before sharing with Technical Partners.
- Folkehelseinstituttet (NIPH) - Cancer Registry of NorwaycoreData Provider contributing retrospective cancer registry data already available in electronic format.
- MOR Research Applications LtdcoreData Provider and Data Controller from Israeli healthcare system, collecting and sharing clinical data for the project.
- Centro Hospitalar de Vila Nova de Gaia/Espinho EPEcorePortuguese Data Provider contributing clinical data to the AI4LUNGS platform.
- Fundacio Privada Institut d'Investigacio Oncologica de VallHebron (VHIO)coreSpanish oncology institute providing clinical data for AI model training.
- I3S - Instituto de Investigacao e Inovacao em Saude da Universidade do PortocoreTechnical Partner from Portugal contributing to AI platform development.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
AI4LUNGS competitors and assessment
Company assessmentDirect peers
- Lunit: Lunit develops AI-powered medical imaging analysis with a strong focus on chest X-ray and lung nodule detection. Comparable to AI4LUNGS's imaging-based diagnostic and clinical decision support capabilities for respiratory disease.
- Annalise.ai: Annalise.ai builds comprehensive AI clinical decision support models covering chest X-ray and CT interpretation. It competes in the same respiratory imaging-AI clinical decision support category as AI4LUNGS.
- Optellum: Optellum is a commercial AI clinical decision support platform focused on lung cancer detection and pulmonary nodule management. It directly overlaps AI4LUNGS's core use case of AI-driven lung cancer stratification and respiratory disease diagnosis.
- Thirona: Thirona specializes in AI-based lung CT analysis for quantification of lung disease, including COPD and interstitial lung disease. Closely aligned with AI4LUNGS's ILD and respiratory disease focus.
- Riverain Technologies: Riverain Technologies offers AI tools for chest X-ray and CT interpretation focused on lung cancer and pulmonary disease. Direct overlap with AI4LUNGS's clinical decision support for respiratory disease diagnosis.
Broad incumbents
- Arterys: Arterys (now part of Tempus) provides a cloud-native medical imaging AI platform with lung and cardiac applications. Comparable as a multi-modal clinical imaging AI infrastructure peer.
- DeepHealth (RadNet): DeepHealth, a subsidiary of RadNet, provides AI-powered lung cancer screening and chest imaging solutions. Comparable as a broader clinical AI incumbent targeting respiratory disease screening and diagnosis.
- Aidoc: Aidoc is a broad medical imaging AI platform deployed across multiple specialties including chest and lung imaging. Larger, more established incumbent operating in the same clinical AI imaging space as AI4LUNGS.
Emerging players
- Quibim: Quibim is an EU-based (Valencia) medical imaging AI company with strengths in lung and oncology imaging biomarkers. Comparable regional and specialty overlap with AI4LUNGS's lung cancer and imaging focus.
- Behold.ai: Behold.ai develops AI-based radiology triage and diagnostic support with chest X-ray capabilities. Comparable as an emerging player in AI clinical decision support for respiratory imaging.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
AI4LUNGS social profiles
Digital presenceAI4LUNGS financial estimates
Financial estimateRevenue estimate
Valuation estimate
AI4LUNGS leadership team
Management profileNumber of profiles
Profiles10 records
AI4LUNGS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AI4LUNGS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AI4LUNGS
What does AI4LUNGS do?
AI4LUNGS develops an AI-based software platform for the diagnosis, prognosis, and treatment of respiratory diseases including lung cancer, ILD, IPF, COPD, and COVID-19. The platform combines multi-modal data integration, digital twin technology, and clinical decision support tools to provide guideline-based and AI-generated recommendations for clinicians managing respiratory patients.
Is AI4LUNGS a public or private company?
AI4LUNGS is a private company. It is classified as unknown and is currently operating.
When was AI4LUNGS founded?
AI4LUNGS was founded in 2024. It employs 51 to 100 people.
Where is AI4LUNGS based?
AI4LUNGS is headquartered in Porto Carreiro, Portugal, in the Europe region.
How does AI4LUNGS make money?
One revenue line is on record: EU Research Grant Funding.
Who are AI4LUNGS's main competitors?
Direct peers on record are Lunit, Annalise.ai, Optellum, Thirona and Riverain Technologies. Broad incumbents are Arterys, DeepHealth (RadNet) and Aidoc. Emerging players are Quibim and Behold.ai.
Does AI4LUNGS have an API?
No public API is recorded for AI4LUNGS.
What industry is AI4LUNGS in?
AI4LUNGS's product category is Clinical Decision Support Systems. Its primary akta.pro industry code is HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 541511 and its SIC code is 7371.